No material corporate announcements were identified for Gilead Sciences Inc. (GILD) in the 30 days preceding this report's generation date of 2026-09-19. The prior briefing dated 2026-09-11 noted a comparable absence of discrete news events, with analysis anchored to verified financial filings and transaction records. The briefing from 2026-08-13 similarly reflected no discrete corporate disclosures during that period [Brief - 2026-09-11].
For the trailing twelve months ended 2026-06-30, Gilead Sciences reported revenue of $30.46 billion, representing year-over-year growth of approximately 10.2%. Net income for the same period was negative $3.24 billion, producing a net margin of -10.6% and an operating margin of -8.2%. Gross margin stood at 64.95%. The company held $3.18 billion in cash against total debt of $28.66 billion. EPS declined 641.7% year-over-year, and no P/E ratio is calculable given the net loss position. Market capitalisation was recorded at approximately $186.3 billion [SEC 10-Q - GILD - 2026-06-30].
Insider activity in September 2026 comprised 33 transactions with a net selling direction, totalling a net disposal value of approximately $6.50 million [SEC Form 4 - GILD - 2026-09]. On the institutional side, four notable firms opened new positions in GILD during the most recent 13F reporting period: Citadel (Ken Griffin), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio). These simultaneous new entries from multiple large institutional managers represent the primary trigger for this report [SEC 13F - Citadel - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macro environment as of this report's generation date shows the 10-year US Treasury yield (DGS10) at 4.94% and the 2-year yield (DGS2) at 4.67%, producing a normal yield curve spread of approximately 27 basis points [FRED DGS10] [FRED DGS2]. This rate environment reflects ongoing monetary conditions that form part of the broader context in which Gilead's debt load of $28.66 billion and financing costs sit.